{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:48:46Z","timestamp":1790426926710,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Osilodrostat is a new 11\u03b2-hydroxylase inhibitor with a mode of action analogous to Metyrapone. The objective of this study was to compare steroidogenic profiles in patients treated with either Osilodrostat or Metyrapone for adrenocorticotrophic hormone (ACTH)-dependent Cushing's syndrome (CS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients followed up at Cochin hospital Endocrinology department between March 2019 and December 2021 for an ACTH-dependent CS, controlled by either Osilodrostat or Metyrapone, were included. A serum profile of five steroids (cortisol, 11-deoxycortisol, 17-hydroxyprogesterone, androstenedione and testosterone) was determined using UPLC- tandem mass spectrometry (UPLC-MS\/MS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nineteen patients treated with Osilodrostat, eight patients treated with Metyrapone and six patients treated with consecutive Metyrapone then Osilodrostat were included. Hypocortisolism (basal cortisol &amp;lt;100 nmol\/L) was found in 48% of patients treated with Osilodrostat and 7% of patients treated with Metyrapone. 11-deoxycortisol and androstenedione levels were higher in patients treated with Metyrapone (80.9 (2.2\u2013688.4) and 14.9 (2.5\u201354.3) nmol\/L, respectively) than in patients treated with Osilodrostat (10.3 (0.5\u201371.9) and 4.0 (0.3\u201313.3) nmol\/L) (P\u2009=\u20090.0009 and P\u2009=\u20090.0005). Testosterone level in women was also higher in Metyrapone group (3.3 (0.93\u20134.82) nmol\/L vs 1.31(0.13\u20135.09) nmol\/L, P\u2009=\u20090.0146). CYP11B1 activity (11-deoxycortisol\/cortisol) was not significantly different between the two groups. CYP21A2 activity (17OHprogesterone\/11-deoxycortisol) and CYP17A1 activity (17OHprogesterone\/androstenedione) were significantly decreased in Osilodrostat group (P\u2009&amp;lt;\u20090.0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with ACTH-dependent CS, the use of CYP11B1 inhibitors in routine care suggests that Osilodrostat has a less specific effect on the inhibition of steroidogenic enzymes than Metyrapone. This might explain a smaller increase in 11-deoxycortisol and androgen levels in patients treated with Osilodrostat.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1530\/eje-22-0208","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T15:38:15Z","timestamp":1655221095000},"page":"315-322","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":31,"title":["Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6628-8807","authenticated-orcid":false,"given":"Fid\u00e9line","family":"Bonnet-Serrano","sequence":"first","affiliation":[{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, UF d'Hormonologie \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"},{"name":"Institut Cochin, Inserm U1016-CNRS UMR8104-Universit\u00e9 de Paris , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Poirier","sequence":"additional","affiliation":[{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, Service d'Endocrinologie et Maladies M\u00e9taboliques \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vaczlavik","sequence":"additional","affiliation":[{"name":"Institut Cochin, Inserm U1016-CNRS UMR8104-Universit\u00e9 de Paris , Paris, France"},{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, Service d'Endocrinologie et Maladies M\u00e9taboliques \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Laguillier-Morizot","sequence":"additional","affiliation":[{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, UF d'Hormonologie \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"},{"name":"Facult\u00e9 de Pharmacie Paris Centre, Universit\u00e9 de Paris , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Blanchet","sequence":"additional","affiliation":[{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital , Paris, France"},{"name":"UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, PRES Sorbonne Paris Cit\u00e9, University of Paris , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-6968","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Baron","sequence":"additional","affiliation":[{"name":"Hopital Europeen Georges Pompidou, Physiology , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Guignat","sequence":"additional","affiliation":[{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, Service d'Endocrinologie et Maladies M\u00e9taboliques \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bessiene","sequence":"additional","affiliation":[{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, Service d'Endocrinologie et Maladies M\u00e9taboliques \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9opoldine","family":"Bricaire","sequence":"additional","affiliation":[{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, Service d'Endocrinologie et Maladies M\u00e9taboliques \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Groussin","sequence":"additional","affiliation":[{"name":"Institut Cochin, Inserm U1016-CNRS UMR8104-Universit\u00e9 de Paris , Paris, France"},{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, Service d'Endocrinologie et Maladies M\u00e9taboliques \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Assi\u00e9","sequence":"additional","affiliation":[{"name":"Institut Cochin, Inserm U1016-CNRS UMR8104-Universit\u00e9 de Paris , Paris, France"},{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, Service d'Endocrinologie et Maladies M\u00e9taboliques \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Guibourdenche","sequence":"additional","affiliation":[{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, UF d'Hormonologie \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"},{"name":"Facult\u00e9 de Pharmacie Paris Centre, Universit\u00e9 de Paris , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2551-3008","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[{"name":"Institut Cochin, Inserm U1016-CNRS UMR8104-Universit\u00e9 de Paris , Paris, France"},{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris, Service d'Endocrinologie et Maladies M\u00e9taboliques \u2013 H\u00f4pitaux Universitaires Paris-Centre , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"2023010809170373300_bib1","first-page":"847","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet: Diabetes and Endocrinology"},{"key":"2023010809170373300_bib2","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170373300_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"European Journal of Endocrinology"},{"key":"2023010809170373300_bib4","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170373300_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clinical Endocrinology"},{"key":"2023010809170373300_bib6","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170373300_bib7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","article-title":"Metyrapone treatment in Cushing's syndrome: a real-life study","volume":"62","author":"Ceccato","year":"2018","journal-title":"Endocrine"},{"key":"2023010809170373300_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/clinem\/dgaa778","article-title":"Adrenally directed medical therapies for Cushing syndrome","volume":"106","author":"Tritos","year":"2021","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170373300_bib9","first-page":"296","article-title":"Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"19","author":"Wang","year":"2015","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"2023010809170373300_bib10","first-page":"748","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet: Diabetes and Endocrinology"},{"key":"2023010809170373300_bib11","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170373300_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"2023010809170373300_bib13","doi-asserted-by":"crossref","first-page":"L13","DOI":"10.1530\/EJE-21-0147","article-title":"Rapid control of severe ectopic Cushing's syndrome by oral osilodrostat monotherapy","volume":"184","author":"Bessi\u00e8ne","year":"2021","journal-title":"European Journal of Endocrinology"},{"key":"2023010809170373300_bib14","doi-asserted-by":"crossref","first-page":"A516","DOI":"10.1210\/jendso\/bvab048.1055","article-title":"Osilodrostat is an effective and well-tolerated treatment for Cushing's disease (CD): results from a phase III study with an upfront, randomized, double-blind, placebo-controlled phase (LINC 4)","volume":"5","author":"Gadelha","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"2023010809170373300_bib15","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-21-1008","article-title":"Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas","volume":"186","author":"Tabarin","year":"2022","journal-title":"European Journal of Endocrinology"},{"key":"2023010809170373300_bib16","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1210\/jc.2019-00217","article-title":"Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in vitro study","volume":"104","author":"Creemers","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170373300_bib17"},{"key":"2023010809170373300_bib18","doi-asserted-by":"crossref","first-page":"A515","DOI":"10.1210\/jendso\/bvab048.1053","article-title":"Metyrapone treatment in endogenous Cushing's syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III\/IV study","volume":"5","author":"Nieman","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"2023010809170373300_bib19"},{"key":"2023010809170373300_bib20","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","article-title":"Approach to the patient treated with steroidogenesis inhibitors","volume":"106","author":"Castinetti","year":"2021","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170373300_bib21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12916-021-02080-8","article-title":"The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions","volume":"19","author":"Melau","year":"2021","journal-title":"BMC Medicine"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/187\/2\/EJE-22-0208.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/187\/2\/EJE-22-0208.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/2\/315\/48515670\/eje-22-0208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/2\/315\/48515670\/eje-22-0208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:17:59Z","timestamp":1676391479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/187\/2\/315\/6972045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eje-22-0208","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8]]},"published":{"date-parts":[[2022,7,4]]}}}